The GSE18497 dataset, the only one available with matched diagnosis-relapse paired samples, reported comparable levels of CD1 gene expression in B-ALL and T-ALL at diagnosis and at relapse (Fig. 1b), supporting the immunological targeting of CD1 molecules at both early and late stages of these malignancies. Here, CD1A is linked to acute lymphoblastic leukemia.